OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected in early Hilary to allow all events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed as soon as possible.
If you have any questions, please contact halo@digital.ox.ac.uk
The lymphatic vessels were once considered like ‘pipes’ that drain excess fluid, lipids and immune cells from tissues back to the blood circulation. We now know that lymphatic vessels and lymph nodes are dynamic structures, constantly changing in response to the surrounding environment, communicating with tissues such as fat and actively regulating the transport of molecules and cells to influence health and disease. The lymphatic system has also been found to play an active role in a range of diseases from cancer to inflammatory and metabolic diseases. Join me to hear about our adventures developing new ways to deliver medicines into the lymphatics and better treat metabolic and inflammatory diseases.
Biography:
Natalie Trevaskis is a Professor, Pharmacist and Heads the Lymphatic Medicine Laboratory at the Monash Institute of Pharmaceutical Sciences, Melbourne, Australia. Her research program is focussed on the role of lymphatics in acute, inflammatory and metabolic diseases, and understanding the delivery of therapeutics and vaccines to the lymphatics to treat these diseases. She has extensive experience in biopharmaceutics, pharmacokinetics and delivery of a range of therapeutic types.
Natalie’s research has resulted in >100 peer reviewed papers (9848 cites) including significant papers in Nature, Nature Metabolism, Nature Nano, Nature Rev Drug Discovery, Angew Chemie, J Control Rel etc. She is also an inventor of 10 patent families (>60 individual patents), including for a lymph-directing prodrug technology licensed to Seaport Therapeutics with three candidates currently in clinical trials. Natalie has worked and consulted extensively with industry (Pfizer, Novartis, Astra Zeneca, Eli Lilly, Amgen, Genentech, Janssen, Protagonist, PureTech Health, Noxopharm etc.) to solve drug delivery problems.
Natalie has received several notable academic prizes. From 2022-24, Natalie was named a Clarivate highly cited (Hi-Ci) researcher in pharmacology (top 0.1% or ~120 worldwide). She received the Vice Chancellor’s Researcher of the Year for Monash University in 2025.
